CT1812 biomarker signature from a meta-analysis of CSF proteomic findings from two Phase 2 clinical trials in Alzheimer's disease.

Alzheimers Dement · 2024 · PMC11485314 · PMID 39166791

Europe PMC DOI

hedged sentence

—

closest p

—

boldest claim

The sentences

a decreasing trendno p-value reported

As an additional finding related to APP, the abundance of LDLR‐related protein (LRP1), an LDL receptor family member, in CSF was significantly decreased in CT1812 versus placebo in the SPARC trial, with a decreasing trend in the meta‐analysis.

also in 47,180 other papers

Quoted from the open-access full text in Europe PMC under the licence the publisher applied. The sentence is reproduced exactly as published; the emphasis is ours.